Cargando…
Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
BACKGROUND: Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685134/ https://www.ncbi.nlm.nih.gov/pubmed/29184391 http://dx.doi.org/10.2147/DDDT.S136957 |
_version_ | 1783278591256035328 |
---|---|
author | Setrerrahmane, Sarra Yu, Jian Hao, Jingchao Zheng, Heng Xu, Hanmei |
author_facet | Setrerrahmane, Sarra Yu, Jian Hao, Jingchao Zheng, Heng Xu, Hanmei |
author_sort | Setrerrahmane, Sarra |
collection | PubMed |
description | BACKGROUND: Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additional antiproliferative effect, are two peptides designed in our laboratory targeting α(v)β(3) and α(5)β(1) integrins, respectively. The low molecular weight of the two peptides renders their recombinant expression very difficult, and the complicated structure of AP25 makes its chemical synthesis restricted, which presents a big challenge for its development. METHODS: Bifunctional peptides designed by the ligation of HM-3 and AP25, using linkers with different flexibility, were prepared using recombinant DNA technology in Escherichia coli. The fusion peptides were expressed in a modified auto-induction medium based on a mixture of glucose, glycerol, and lactose as carbon substrates and NH(4)(+) as nitrogen source without any amino acid or other elements. Subsequently, the antiangiogenic, antiproliferative, and cell adhesion assays were conducted to evaluate the bioactivity of the two fusion peptides. RESULTS: The peptides were successfully expressed in a soluble form without any induction, which allows the culture to reach higher cell density before protein expression occurs. Human umbilical vein endothelial cell migration assay and chick embryo chorioallantoic membrane assay showed, at low doses, a significantly increased antiangiogenic effect (>75%) of the purified products compared with the single molecules. Meanwhile, MTT assay confirmed their enhanced antitumor activity against gastric cancer cell line MGC-803; however, no significant effect was observed on hepatoma HepG2 cells and no cytotoxicity on normal human lens epithelial cell SRA01/04 and human epithelial esophageal cells. CONCLUSION: Bifunctional molecules with antiangiogenic and antiproliferative effects were obtained by using this technique, which presents an alternative for small peptide production, instead of the conventional chemical method. The increased molecular weight facilitates the peptide expression with a simultaneous improvement in their stability and biological activity. |
format | Online Article Text |
id | pubmed-5685134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56851342017-11-28 Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli Setrerrahmane, Sarra Yu, Jian Hao, Jingchao Zheng, Heng Xu, Hanmei Drug Des Devel Ther Original Research BACKGROUND: Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additional antiproliferative effect, are two peptides designed in our laboratory targeting α(v)β(3) and α(5)β(1) integrins, respectively. The low molecular weight of the two peptides renders their recombinant expression very difficult, and the complicated structure of AP25 makes its chemical synthesis restricted, which presents a big challenge for its development. METHODS: Bifunctional peptides designed by the ligation of HM-3 and AP25, using linkers with different flexibility, were prepared using recombinant DNA technology in Escherichia coli. The fusion peptides were expressed in a modified auto-induction medium based on a mixture of glucose, glycerol, and lactose as carbon substrates and NH(4)(+) as nitrogen source without any amino acid or other elements. Subsequently, the antiangiogenic, antiproliferative, and cell adhesion assays were conducted to evaluate the bioactivity of the two fusion peptides. RESULTS: The peptides were successfully expressed in a soluble form without any induction, which allows the culture to reach higher cell density before protein expression occurs. Human umbilical vein endothelial cell migration assay and chick embryo chorioallantoic membrane assay showed, at low doses, a significantly increased antiangiogenic effect (>75%) of the purified products compared with the single molecules. Meanwhile, MTT assay confirmed their enhanced antitumor activity against gastric cancer cell line MGC-803; however, no significant effect was observed on hepatoma HepG2 cells and no cytotoxicity on normal human lens epithelial cell SRA01/04 and human epithelial esophageal cells. CONCLUSION: Bifunctional molecules with antiangiogenic and antiproliferative effects were obtained by using this technique, which presents an alternative for small peptide production, instead of the conventional chemical method. The increased molecular weight facilitates the peptide expression with a simultaneous improvement in their stability and biological activity. Dove Medical Press 2017-11-08 /pmc/articles/PMC5685134/ /pubmed/29184391 http://dx.doi.org/10.2147/DDDT.S136957 Text en © 2017 Setrerrahmane et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Setrerrahmane, Sarra Yu, Jian Hao, Jingchao Zheng, Heng Xu, Hanmei Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title | Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title_full | Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title_fullStr | Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title_full_unstemmed | Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title_short | Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli |
title_sort | novel production method of innovative antiangiogenic and antitumor small peptides in escherichia coli |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685134/ https://www.ncbi.nlm.nih.gov/pubmed/29184391 http://dx.doi.org/10.2147/DDDT.S136957 |
work_keys_str_mv | AT setrerrahmanesarra novelproductionmethodofinnovativeantiangiogenicandantitumorsmallpeptidesinescherichiacoli AT yujian novelproductionmethodofinnovativeantiangiogenicandantitumorsmallpeptidesinescherichiacoli AT haojingchao novelproductionmethodofinnovativeantiangiogenicandantitumorsmallpeptidesinescherichiacoli AT zhengheng novelproductionmethodofinnovativeantiangiogenicandantitumorsmallpeptidesinescherichiacoli AT xuhanmei novelproductionmethodofinnovativeantiangiogenicandantitumorsmallpeptidesinescherichiacoli |